Acrotech BioPharma
Acrotech Biopharma Inc is a pharmaceutical company dedicated to developing, acquiring, and commercializing innovative medications across various fields including oncology, hematology, dermatology, neurology, and rare diseases. The company emphasizes patient safety, scientific advancement, and building long-term stakeholder relationships, with a broad portfolio of branded products and strategic acquisitions.
Industries
Nr. of Employees
medium (51-250)
Acrotech BioPharma
279 Princeton Hightstown Rd. East Windsor, NJ 08520
Patents
Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
US-12527750-B2
View DetailsPharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
US-12016830-B2
View Details
Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
US-12527750-B2
View DetailsPharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
US-12016830-B2
View DetailsProducts
Oral corticosteroid formulation for combination oncology regimens
Oral corticosteroid indicated for use in combination anti-myeloma regimens, with documented prescribing information and systemic safety considerations.
Intravenous alkylating-agent formulation for conditioning and palliative use
Intravenous alkylating agent used in conditioning regimens (including myeloablative settings) and palliative treatment in hematologic oncology, with defined monitoring and supportive care requirements.
Liposomal vinca-alkaloid class injectable formulation
Liposomal formulation of a vinca-alkaloid class agent for intravenous administration with specific handling and neuropathy/extravasation risk guidance.
Intravenous antifolate chemotherapy for selected lymphomas
Intravenous antifolate chemotherapy used for selected peripheral T‑cell lymphomas with associated monitoring and supportive care requirements.
HDAC-inhibitor intravenous therapy for relapsed/refractory lymphomas
Intravenous histone deacetylase inhibitor indicated for certain relapsed or refractory peripheral T‑cell lymphomas, with hematologic and hepatic monitoring guidance.
Radiolabeled antibody-based radioimmunotherapy regimen
Radiolabeled antibody-based therapy administered in specialty centers with institutional radiation-safety procedures and long-term hematologic surveillance requirements.
Oral corticosteroid formulation for combination oncology regimens
Oral corticosteroid indicated for use in combination anti-myeloma regimens, with documented prescribing information and systemic safety considerations.
Intravenous alkylating-agent formulation for conditioning and palliative use
Intravenous alkylating agent used in conditioning regimens (including myeloablative settings) and palliative treatment in hematologic oncology, with defined monitoring and supportive care requirements.
Liposomal vinca-alkaloid class injectable formulation
Liposomal formulation of a vinca-alkaloid class agent for intravenous administration with specific handling and neuropathy/extravasation risk guidance.
Intravenous antifolate chemotherapy for selected lymphomas
Intravenous antifolate chemotherapy used for selected peripheral T‑cell lymphomas with associated monitoring and supportive care requirements.
HDAC-inhibitor intravenous therapy for relapsed/refractory lymphomas
Intravenous histone deacetylase inhibitor indicated for certain relapsed or refractory peripheral T‑cell lymphomas, with hematologic and hepatic monitoring guidance.
Radiolabeled antibody-based radioimmunotherapy regimen
Radiolabeled antibody-based therapy administered in specialty centers with institutional radiation-safety procedures and long-term hematologic surveillance requirements.
Services
Engagements to evaluate, negotiate and consummate licensing, acquisition and commercialization collaborations for specialty therapies; includes deal structuring and leveraging contract manufacturing access for supply and scale-up.
Operational programs to support patients and providers with reimbursement navigation, prior authorization and hub coordination to facilitate access to specialty therapies.
Creation and distribution of clinical guides, treatment summaries, clinic and specialty pharmacy listings and other HCP-facing educational materials via digital portals.
Hosting and centralized support for investigator-initiated clinical research related to company-managed therapies, providing product and safety information and point-of-contact resources.
Centralized phone and email channels for adverse event reporting, safety inquiries and facilitation of regulatory reporting obligations.
Engagements to evaluate, negotiate and consummate licensing, acquisition and commercialization collaborations for specialty therapies; includes deal structuring and leveraging contract manufacturing access for supply and scale-up.
Operational programs to support patients and providers with reimbursement navigation, prior authorization and hub coordination to facilitate access to specialty therapies.
Creation and distribution of clinical guides, treatment summaries, clinic and specialty pharmacy listings and other HCP-facing educational materials via digital portals.
Hosting and centralized support for investigator-initiated clinical research related to company-managed therapies, providing product and safety information and point-of-contact resources.
Centralized phone and email channels for adverse event reporting, safety inquiries and facilitation of regulatory reporting obligations.
Expertise Areas
- Oncology product commercialization and U.S. market operations
- Pharmacovigilance and centralized adverse-event reporting
- Regulatory affairs and milestone-driven regulatory coordination
- Patient access, reimbursement navigation and hub services
Key Technologies
- Liposomal drug formulation
- Radiolabeled antibody therapy and radiochemistry
- Intravenous injectable formulation development and administration protocols
- GMP biologics and small-molecule manufacturing